BACKGROUND: The authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose of thebivalent HPV vaccine compared with women who received multiple doses and unvaccinated women. METHODS:HPV infections were compared between HPV16or 18-vaccinated women aged 18 to 25 years who received one (N = 112), two (N = 62), or three (N = 1365) doses, and age- and geography-matched unvaccinated women (N = 1783) in the long-term follow-up of the Costa Rica HPV Vaccine Trial. Cervical HPV infections were measured at two study visits, approximately 9 and 11 years after initial HPV vaccination, using National Cancer Institute next-generation sequencing TypeSeq1 assay. VE and 95% confidence intervals (CIs) were estimated. HPV16 or 18 antibody levels were measured in all one- and two-dose women, and a subset of three-dose women, using a virus-like particle-based enzyme-linked immunosorbent assay (n = 448). RESULTS: Median follow-up for the HPV-vaccinated group was 11.3 years (interquartile range = 10.9-11.7 years) and did not vary by dose group. VE against prevalent HPV16 or 18 infection was 80.2% (95% CI = 70.7% to 87.0%) among three-dose, 83.8% (95% CI = 19.5% to 99.2%) among two-dose, and 82.1% (95% CI = 40.2% to 97.0%) among single-dose women. HPV16 or 18 antibody levels did not qualitatively decline between years four and 11 regardless of the number of doses given, although one-dose titers continue to be statistically significantly lower compared with two- and three-dose titers. CONCLUSION: More than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
RCT Entities:
BACKGROUND: The authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose of the bivalent HPV vaccine compared with women who received multiple doses and unvaccinated women. METHODS:HPV infections were compared between HPV16 or 18-vaccinated women aged 18 to 25 years who received one (N = 112), two (N = 62), or three (N = 1365) doses, and age- and geography-matched unvaccinated women (N = 1783) in the long-term follow-up of the Costa Rica HPV Vaccine Trial. Cervical HPV infections were measured at two study visits, approximately 9 and 11 years after initial HPV vaccination, using National Cancer Institute next-generation sequencing TypeSeq1 assay. VE and 95% confidence intervals (CIs) were estimated. HPV16 or 18 antibody levels were measured in all one- and two-dose women, and a subset of three-dose women, using a virus-like particle-based enzyme-linked immunosorbent assay (n = 448). RESULTS: Median follow-up for the HPV-vaccinated group was 11.3 years (interquartile range = 10.9-11.7 years) and did not vary by dose group. VE against prevalent HPV16 or 18 infection was 80.2% (95% CI = 70.7% to 87.0%) among three-dose, 83.8% (95% CI = 19.5% to 99.2%) among two-dose, and 82.1% (95% CI = 40.2% to 97.0%) among single-dose women. HPV16 or 18 antibody levels did not qualitatively decline between years four and 11 regardless of the number of doses given, although one-dose titers continue to be statistically significantly lower compared with two- and three-dose titers. CONCLUSION: More than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
Authors: Troy J Kemp; Alfonso García-Piñeres; Roni T Falk; Sylviane Poncelet; Francis Dessy; Sandra L Giannini; Ana Cecilia Rodriguez; Carolina Porras; Rolando Herrero; Allan Hildesheim; Ligia A Pinto Journal: Vaccine Date: 2008-05-19 Impact factor: 3.641
Authors: Sarah Wagner; David Roberson; Joseph Boland; Meredith Yeager; Michael Cullen; Lisa Mirabello; S Terence Dunn; Joan Walker; Rosemary Zuna; Mark Schiffman; Nicolas Wentzensen Journal: J Clin Microbiol Date: 2019-04-26 Impact factor: 5.948
Authors: Mahboobeh Safaeian; Arpita Ghosh; Carolina Porras; Shih-Wen Lin; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Troy Kemp; Paula Gonzalez; Nicolas Wentzensen; Mark Esser; Ariane Meuree; Katie Matys; Wim Quint; Leen-Jan van Doorn; Mark E Sherman; Rolando Herrero; Ligia A Pinto; Allan Hildesheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-07-02 Impact factor: 4.254
Authors: Aimée R Kreimer; Ana Cecilia Rodriguez; Allan Hildesheim; Rolando Herrero; Carolina Porras; Mark Schiffman; Paula González; Diane Solomon; Silvia Jiménez; John T Schiller; Douglas R Lowy; Wim Quint; Mark E Sherman; John Schussler; Sholom Wacholder Journal: J Natl Cancer Inst Date: 2011-09-09 Impact factor: 13.506
Authors: Barbara Romanowski; Tino F Schwarz; Linda Ferguson; Klaus Peters; Marc Dionne; Ulrich Behre; Karin Schulze; Peter Hillemanns; Pemmaraju Suryakiran; Florence Thomas; Frank Struyf Journal: Hum Vaccin Immunother Date: 2015-07-15 Impact factor: 3.452
Authors: Aimée R Kreimer; Rolando Herrero; Joshua N Sampson; Carolina Porras; Douglas R Lowy; John T Schiller; Mark Schiffman; Ana Cecilia Rodriguez; Stephen Chanock; Silvia Jimenez; John Schussler; Mitchell H Gail; Mahboobeh Safaeian; Troy J Kemp; Bernal Cortes; Ligia A Pinto; Allan Hildesheim; Paula Gonzalez Journal: Vaccine Date: 2018-02-01 Impact factor: 3.641
Authors: Marc Brisson; Élodie Bénard; Mélanie Drolet; Johannes A Bogaards; Iacopo Baussano; Simopekka Vänskä; Mark Jit; Marie-Claude Boily; Megan A Smith; Johannes Berkhof; Karen Canfell; Harrell W Chesson; Emily A Burger; Yoon H Choi; Birgitte Freiesleben De Blasio; Sake J De Vlas; Giorgio Guzzetta; Jan A C Hontelez; Johannes Horn; Martin R Jepsen; Jane J Kim; Fulvio Lazzarato; Suzette M Matthijsse; Rafael Mikolajczyk; Andrew Pavelyev; Matthew Pillsbury; Leigh Anne Shafer; Stephen P Tully; Hugo C Turner; Cara Usher; Cathal Walsh Journal: Lancet Public Health Date: 2016-09-27
Authors: Sarah Wagner; David Roberson; Joseph Boland; Aimée R Kreimer; Meredith Yeager; Michael Cullen; Lisa Mirabello; S Terence Dunn; Joan Walker; Rosemary Zuna; Carolina Porras; Bernal Cortes; Joshua Sampson; Rolando Herrero; Ana Cecilia Rodriguez; Wim Quint; Leen-Jan Van Doorn; Allan Hildesheim; Mark Schiffman; Nicolas Wentzensen Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Carolina Porras; Joshua N Sampson; Rolando Herrero; Mitchell H Gail; Bernal Cortés; Allan Hildesheim; Jean Cyr; Byron Romero; John T Schiller; Christian Montero; Ligia A Pinto; John Schussler; Karla Coronado; Mónica S Sierra; Jane J Kim; Catherine M Torres; Loretto Carvajal; Sarah Wagner; Nicole G Campos; Rebecca Ocampo; Troy J Kemp; Michael Zuniga; Douglas R Lowy; Carlos Avila; Stephen Chanock; Ariane Castrillo; Yenory Estrada; Gloriana Barrientos; Cindy Monge; María Y Oconitrillo; Aimée R Kreimer Journal: Vaccine Date: 2021-11-29 Impact factor: 3.641
Authors: Jaimie Z Shing; Shangying Hu; Rolando Herrero; Allan Hildesheim; Carolina Porras; Joshua N Sampson; John Schussler; John T Schiller; Douglas R Lowy; Mónica S Sierra; Loretto Carvajal; Aimée R Kreimer Journal: Lancet Oncol Date: 2022-06-13 Impact factor: 54.433
Authors: Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Carolina Porras; Sabrina H Tsang; Rolando Herrero; Diego Guillén; Teresa M Darragh; Mark H Stoler; Allan Hildesheim; Sarah Wagner; Joseph Boland; Douglas R Lowy; John T Schiller; Mark Schiffman; John Schussler; Mitchell H Gail; Wim Quint; Rebeca Ocampo; Jorge Morales; Ana C Rodríguez; Shangying Hu; Joshua N Sampson; Aimée R Kreimer Journal: Lancet Oncol Date: 2020-12 Impact factor: 41.316
Authors: Zheng Quan Toh; Fiona M Russell; Suzanne M Garland; Edward K Mulholland; George Patton; Paul V Licciardi Journal: JNCI Cancer Spectr Date: 2021-03-02
Authors: Fan Yang; Filipe C Mariz; Xueer Zhao; Gloria Spagnoli; Simone Ottonello; Martin Müller Journal: Front Immunol Date: 2020-12-04 Impact factor: 7.561
Authors: Kanan T Desai; Brian Befano; Zhiyun Xue; Helen Kelly; Nicole G Campos; Didem Egemen; Julia C Gage; Ana-Cecilia Rodriguez; Vikrant Sahasrabuddhe; David Levitz; Paul Pearlman; Jose Jeronimo; Sameer Antani; Mark Schiffman; Silvia de Sanjosé Journal: Int J Cancer Date: 2021-12-06 Impact factor: 7.316
Authors: Aruna Kamineni; Paula R Blasi; Gabrielle D Gundersen; Malia Oliver; John B Dunn; Denise A Galloway; Margaret M Madeleine Journal: Infect Dis (Auckl) Date: 2021-05-20